375 related articles for article (PubMed ID: 33596188)
21. Incidence of tumor lysis syndrome in patients with acute myeloid leukemia undergoing low-intensity induction with venetoclax.
Diao S; Nichols ED; DiNardo C; Konopleva M; Ning J; Qiao W; Maiti A; DiPippo AJ
Am J Hematol; 2021 Mar; 96(3):E65-E68. PubMed ID: 33259075
[No Abstract] [Full Text] [Related]
22. Venetoclax in combination with azacitidine in Japanese patients with acute myeloid leukaemia: phase 1 trial findings.
Taniguchi S; Yamauchi T; Choi I; Fukuhara N; Potluri J; Salem AH; Hong WJ; Honda H; Nishimura Y; Okubo S; Usuki K
Jpn J Clin Oncol; 2021 May; 51(6):857-864. PubMed ID: 33712849
[TBL] [Abstract][Full Text] [Related]
23. Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents.
Othman TA; Mei M; Zhang J; Aldoss I; Stein A; Forman SJ; Marcucci G; Pullarkat V
Am J Hematol; 2021 May; 96(5):E140-E143. PubMed ID: 33524204
[No Abstract] [Full Text] [Related]
24. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
DiNardo CD; Pratz K; Pullarkat V; Jonas BA; Arellano M; Becker PS; Frankfurt O; Konopleva M; Wei AH; Kantarjian HM; Xu T; Hong WJ; Chyla B; Potluri J; Pollyea DA; Letai A
Blood; 2019 Jan; 133(1):7-17. PubMed ID: 30361262
[TBL] [Abstract][Full Text] [Related]
25. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia.
Jonas BA; Pollyea DA
Leukemia; 2019 Dec; 33(12):2795-2804. PubMed ID: 31628431
[TBL] [Abstract][Full Text] [Related]
26. Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed/refractory acute myeloid leukemia: Two case reports.
Wang H; Bai J; Pei Z; Zhang B; Wang J; Lian X; Song Q
Medicine (Baltimore); 2020 Nov; 99(47):e23265. PubMed ID: 33217852
[TBL] [Abstract][Full Text] [Related]
27. RUNX1 mutations correlate with response to venetoclax combination therapies in relapsed/refractory acute myeloid leukemia.
Chow S; Tang K; Al-Abri M; Hall V; Tremblay-Lemay R; Rashedi I; Tsui H; Chan SM
Leuk Res; 2021 Dec; 111():106735. PubMed ID: 34735933
[No Abstract] [Full Text] [Related]
28. Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm.
Tremblay D; Feld J; Dougherty M; Czaplinska T; Sanchez G; Kremyanskaya M; Bar-Natan M; Shih AH; Keyzner A; Mascarenhas J
Leuk Res; 2020 Nov; 98():106456. PubMed ID: 33002673
[No Abstract] [Full Text] [Related]
29. Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML).
Tawfik B; Sliesoraitis S; Lyerly S; Klepin HD; Lawrence J; Isom S; Ellis LR; Manuel M; Dralle S; Berenzon D; Powell BL; Pardee T
Ann Hematol; 2014 Jan; 93(1):47-55. PubMed ID: 24149914
[TBL] [Abstract][Full Text] [Related]
30. Venetoclax-induced panniculitis in an acute myeloid leukemia patient.
Liao PW; Wang RC; Chen TC; Teng CJ
Ann Hematol; 2021 May; 100(5):1333-1334. PubMed ID: 33439305
[No Abstract] [Full Text] [Related]
31. Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series.
Wan CL; Zou JY; Qiao M; Yin J; Shen XD; Qiu QC; Liu SB; Xue SL
Leuk Lymphoma; 2021 Dec; 62(13):3300-3303. PubMed ID: 34323656
[No Abstract] [Full Text] [Related]
32. Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine.
Venugopal S; Maiti A; DiNardo CD; Qiao W; Ning J; Loghavi S; Daver NG; Kadia TM; Rausch CR; Alvarado Y; Ohanian M; Sasaki K; Short NJ; Takahashi K; Yilmaz M; Ravandi F; Kantarjian HM; Konopleva MY
Leuk Lymphoma; 2021 Dec; 62(14):3501-3505. PubMed ID: 34474640
[No Abstract] [Full Text] [Related]
33. Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML.
Xie J; Bao X; Xue SL; Shen H; Cen J; Yao L; Pan J; Zhu M; Liu D; Hu X; Wu Q; Zhang J; Dai H; Cao Y; He X; Tang X; Sun AN; Wang Y; Fu J; Qiu H; Yang X; Chen S; Wu D
Blood; 2023 Oct; 142(15):1323-1327. PubMed ID: 37478399
[No Abstract] [Full Text] [Related]
34. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia.
Winters AC; Gutman JA; Purev E; Nakic M; Tobin J; Chase S; Kaiser J; Lyle L; Boggs C; Halsema K; Schowinsky JT; Rosser J; Ewalt MD; Siegele B; Rana V; Schuster S; Abbott D; Stevens BM; Jordan CT; Smith C; Pollyea DA
Blood Adv; 2019 Oct; 3(20):2911-2919. PubMed ID: 31648312
[TBL] [Abstract][Full Text] [Related]
35. Apoptosis targeted therapies in acute myeloid leukemia: an update.
Ball S; Borthakur G
Expert Rev Hematol; 2020 Dec; 13(12):1373-1386. PubMed ID: 33205684
[No Abstract] [Full Text] [Related]
36. Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up.
Shahswar R; Beutel G; Gabdoulline R; Koenecke C; Markel D; Eder M; Stadler M; Gohring G; Schlegelberger B; Trummer A; Krauter J; Thol F; Heuser M
Ann Hematol; 2021 Feb; 100(2):595-599. PubMed ID: 32705308
[No Abstract] [Full Text] [Related]
37. Clinical update on hypomethylating agents.
Duchmann M; Itzykson R
Int J Hematol; 2019 Aug; 110(2):161-169. PubMed ID: 31020568
[TBL] [Abstract][Full Text] [Related]
38. A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia.
Zhu LX; Chen RR; Wang LL; Sun JN; Zhou D; Li L; Qian JJ; Zhang Y; Tong HY; Yu WJ; Meng HT; Mai WY; Xie WZ; Jin J; Ye XJ; Zhu HH
Support Care Cancer; 2022 Aug; 30(8):7031-7038. PubMed ID: 35585204
[TBL] [Abstract][Full Text] [Related]
39. Very long-term efficacy of venetoclax combined with hypomethylating agents in two AML elderly: is it the time for treatment discontinuation strategies?
Niscola P; Gianfelici V; Giovannini M; Piccioni D; Mazzone C; Fabritiis P
Ann Hematol; 2024 May; 103(5):1787-1788. PubMed ID: 38459155
[No Abstract] [Full Text] [Related]
40. Venetoclax plus cytochrome P450 inhibitors without ramp-up strategy led to low risk of tumor lysis syndrome in acute myeloid leukemia.
Cheng FM; Tien JZ; Chen TT; Yeh SP; Lin CC
Ann Hematol; 2020 Sep; 99(9):2193-2195. PubMed ID: 32621180
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]